IQVIA Institute for Human Data Science

💉What can patients expect when receiving gene therapy? The patient journey differs based on whether the therapy is administered in vivo or ex vivo. In vivo treatments, are injected, infused, or administered in a specialized treatment center without the need for collection and external manipulation of the patient’s cells. The ex vivo treatment journey can be seen here in this chart. To learn more about the patient journey in gene therapy, download the Strengthening Pathways for Cell and Gene Therapies report here: https://bit.ly/3LmaA1j #GeneTherapy #CellTherapy #GlobalaHealth

Which cancers have a low survival rate despite significant improvement in therapies? Listen to this clip from the Institute’s Executive Director, Murray Aitken as he walks through the cancers with low to mid survival rates. Catch the whole event here: https://bit.ly/3Wjx2hO. #Oncology #PersonalizedMedicine

We are just one week away from IQVIA Institute’s 2024 Research Forum on Advancing Evidence with Large Datasets in High-Impact Health Research.  Panelists will discuss how to conduct research with effective use of large datasets, combining data and methodologies from multiple fields of research across data science, clinical research, epidemiology, population health, and social research. The IQVIA Institute is proud to present this year’s Research Forum in collaboration with Questrom School of Business, Boston University and Boston University School of Public Health. Deadline to register is today, July 11, at noon EDT. Click the link to register for this free, public event in Boston, next week on July 18-19th: https://lnkd.in/ewzwUe4N

One area that IQVIA Institute has recently been tracking is the impact of illegal online pharmacies in the U.S. We were pleased to see this important data was recently cited in Katherine Eban’s article in Vanity Fair on Why Counterfeit Ozempic a Global-Growth Industry. The data was originally reported in IQVIA Institute’s, Illegal Online Pharmacies in the U.S. report, which used research drawn from a novel methodology developed by IE University and commercialized by Translucent Datalab. To learn more about the nature and use of illegal online pharmacies (IOPs) over recent years and the impact this has on public health and the operation of the distribution system, download the report here: https://bit.ly/3Lk8f74

🔍 New report out now: Rethinking Clinical Trial Country Prioritization The biopharma clinical research ecosystem has undergone significant evolution over the past five years due to technological, environmental, societal, regulatory, and geopolitical shifts. These changes have reshaped clinical trial activities and operations, bringing both opportunities and challenges. 📊 Our latest report explores: ✅ The emergence of new global players in clinical trials. ✅ Execution challenges, delays, capacity concerns, and uncertainties impacting clinical development timelines and patient outcomes. ✅ The critical focus on global diversification of clinical trials. ✅ Trends in enrollment timelines, trial characteristics, and country utilization. ✅ Exploration of countries with high patient recruitment potential. Get your copy of the report: https://lnkd.in/erWtB-qG #ClinicalTrials #GlobalHealth #HealthEquity

💉 Combination therapies are a mainstay of hematology cancer care, and their availability allows for increased patient benefit. Yet IQVIA Institute’s recent report discovered vast differences in access and reimbursement of combination therapies for hematology-oncology drugs across Europe. The Hematologic Cancer Opportunities for Patient Equality (HOPE) report analyzed three combination therapies across Europe and discovered variations in availability and reimbursement. For example, Italy and Greece (>70%) show the highest full rate while Lithuania, Romania, and Ireland have lower rates of full availability (15%-40%). The average time to availability also varies significantly across countries surveyed. What is driving these variations? 🔹 Traditionally, payers have assessed the value of new therapies using criteria suited for monotherapies, which means value assessment frameworks have not been adapted for combination therapies. 🔹 Or if they have, they often cannot fully recognize the value of combination therapy with two novel agents. 🔹 Furthermore, companies can run into negotiation challenges when combination treatments involve two or more manufacturers. Read about the variations in access and reimbursement of hematology-oncology drugs by downloading the report: https://bit.ly/3VW6MsL. #Oncology #PharmaSpending.

⏰ Don’t forget to register for IQVIA Institute’s 2024 Research Forum. The IQVIA Institute is proud to present this year’s Research Forum in collaboration with Questrom School of Business, Boston University and Boston University School of Public Health. The topic is: Advancing Evidence with Large Datasets in High-Impact Health Research. Swipe through to see the four themes of this event. As part of these themes, the 2024 Research Forum will discuss how to conduct research with effective use of large datasets, combining data and methodologies from multiple fields of research across data science, clinical research, epidemiology, population health, and social research. Click the link to register for this free, public event in Boston on July 18-19th: https://lnkd.in/ewzwUe4N

In case you missed it, Katherine Eban recently published an article in Vanity Fair on Why Counterfeit Ozempic a Global-Growth Industry and cited IQVIA Institute’s research in the area of Illegal Online Pharmacies (IOPs). Curious about the overall volume of medicines being ordered by Americans from IOPs? Go to Exhibit 10 in the Use of Medicines in the U.S. 2024: https://bit.ly/3zrBhPA Thank you to Translucent Datalab for collaborating on this data collection.

🗝️ What is the key challenge of the latest personalized medicine therapies in oncology? Ryan Richardson, Chief Strategy Officer at BioNTech SE, shares his thoughts in this clip from IQVIA Institute’s Pre-ASCO Symposium. Watch the whole event here:  https://lnkd.in/eUQt7Vzx #Oncology #PersonalizedMedicine

Are hematology drugs reaching patients across Europe? IQVIA Institute aims to answer this question in our latest report, Hematologic Cancer Opportunities for Patient Equality (HOPE). This chart assesses the volume use of novel hematological cancer medicines, by applying the WHO Defined Daily Dose (WHO-DDD) metric IQVIA audited medicine volumes in this chart. 🩸 There may be differences in the medicines evaluated. This highlights the variability in country-level prioritization of certain types of novel medicines for a variety of cancers. 🩸 The UK and France had utilization levels nearly 50% higher than the European average. Australia, Canada, and Italy also had DDD per capita in 2023 above the European average. 🩸 Central and Eastern European countries tend to have lower utilization of these medicines though all have similar DDD per capita in 2023. These countries range from 37% to 44% below the European average. 🩸 Typically, wealthier countries have higher utilization of essential innovative medicines as these countries tend to have more economic resources to devote to healthcare. Download Hematologic Cancer Opportunities for Patient Equality (HOPE) to learn more about the availability of hematology cancer treatments for patients across countries: https://bit.ly/465Ufrr. #Oncology #PharmaSpending.